Developing epigenetic diagnostics and therapeutics for brain disorders

Irfan A. Qureshi, Mark F. Mehler

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Perturbations in epigenetic mechanisms have emerged as cardinal features in the molecular pathology of major classes of brain disorders. We therefore highlight evidence which suggests that specific epigenetic signatures measurable in central - and possibly even in peripheral tissues - have significant value as translatable biomarkers for screening, early diagnosis, and prognostication; developing molecularly targeted medicines; and monitoring disease progression and treatment responses. We also draw attention to existing and novel therapeutic approaches directed at epigenetic factors and mechanisms, including strategies for modulating enzymes that write and erase DNA methylation and histone/chromatin marks; protein-protein interactions responsible for reading epigenetic marks; and non-coding RNA pathways.

Original languageEnglish (US)
Pages (from-to)732-741
Number of pages10
JournalTrends in Molecular Medicine
Volume19
Issue number12
DOIs
StatePublished - Dec 2013

Fingerprint

Brain Diseases
Epigenomics
Histone Code
Untranslated RNA
Molecular Pathology
DNA Methylation
Therapeutics
Chromatin
Disease Progression
Reading
Early Diagnosis
Proteins
Biomarkers
Enzymes

Keywords

  • Bromodomain
  • Epigenomic
  • Exosome
  • Glioma
  • Histone deacetylase
  • Long non-coding RNA
  • MicroRNA

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine

Cite this

Developing epigenetic diagnostics and therapeutics for brain disorders. / Qureshi, Irfan A.; Mehler, Mark F.

In: Trends in Molecular Medicine, Vol. 19, No. 12, 12.2013, p. 732-741.

Research output: Contribution to journalArticle

@article{fe9a022fac534342b4515e5fc586224d,
title = "Developing epigenetic diagnostics and therapeutics for brain disorders",
abstract = "Perturbations in epigenetic mechanisms have emerged as cardinal features in the molecular pathology of major classes of brain disorders. We therefore highlight evidence which suggests that specific epigenetic signatures measurable in central - and possibly even in peripheral tissues - have significant value as translatable biomarkers for screening, early diagnosis, and prognostication; developing molecularly targeted medicines; and monitoring disease progression and treatment responses. We also draw attention to existing and novel therapeutic approaches directed at epigenetic factors and mechanisms, including strategies for modulating enzymes that write and erase DNA methylation and histone/chromatin marks; protein-protein interactions responsible for reading epigenetic marks; and non-coding RNA pathways.",
keywords = "Bromodomain, Epigenomic, Exosome, Glioma, Histone deacetylase, Long non-coding RNA, MicroRNA",
author = "Qureshi, {Irfan A.} and Mehler, {Mark F.}",
year = "2013",
month = "12",
doi = "10.1016/j.molmed.2013.09.003",
language = "English (US)",
volume = "19",
pages = "732--741",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Developing epigenetic diagnostics and therapeutics for brain disorders

AU - Qureshi, Irfan A.

AU - Mehler, Mark F.

PY - 2013/12

Y1 - 2013/12

N2 - Perturbations in epigenetic mechanisms have emerged as cardinal features in the molecular pathology of major classes of brain disorders. We therefore highlight evidence which suggests that specific epigenetic signatures measurable in central - and possibly even in peripheral tissues - have significant value as translatable biomarkers for screening, early diagnosis, and prognostication; developing molecularly targeted medicines; and monitoring disease progression and treatment responses. We also draw attention to existing and novel therapeutic approaches directed at epigenetic factors and mechanisms, including strategies for modulating enzymes that write and erase DNA methylation and histone/chromatin marks; protein-protein interactions responsible for reading epigenetic marks; and non-coding RNA pathways.

AB - Perturbations in epigenetic mechanisms have emerged as cardinal features in the molecular pathology of major classes of brain disorders. We therefore highlight evidence which suggests that specific epigenetic signatures measurable in central - and possibly even in peripheral tissues - have significant value as translatable biomarkers for screening, early diagnosis, and prognostication; developing molecularly targeted medicines; and monitoring disease progression and treatment responses. We also draw attention to existing and novel therapeutic approaches directed at epigenetic factors and mechanisms, including strategies for modulating enzymes that write and erase DNA methylation and histone/chromatin marks; protein-protein interactions responsible for reading epigenetic marks; and non-coding RNA pathways.

KW - Bromodomain

KW - Epigenomic

KW - Exosome

KW - Glioma

KW - Histone deacetylase

KW - Long non-coding RNA

KW - MicroRNA

UR - http://www.scopus.com/inward/record.url?scp=84888428721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888428721&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2013.09.003

DO - 10.1016/j.molmed.2013.09.003

M3 - Article

VL - 19

SP - 732

EP - 741

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 12

ER -